In this edition, preventive therapies should be offered for migraines; targeting neuropathic symptoms for poststroke pain; PDE5 inhibitors not associated with lower AD, dementia risk and more. Read the full coverage here: Range of preventive therapies should be offered for migraines Poststroke pain may be controlled by targeting neuropathic symptoms Treatment with PDE5 inhibitors not associated with reduced risk for AD, dementia NFL, NFLPA finalize review of updated concussion protocol in wake of Tagovailoa injury Blunt cerebrovascular injury increases risk for ischemic stroke, requires rapid response References: Bottros M. Poststroke pain: What it is, what causes it and how to treat it. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas. Desai RJ, et al. Brain Commun. 2022;doi:10.1093/braincomms/fcac247. Diamond M. Diamond Headache Clinic migraine track: Prevention, treatment. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas. Press Release Stone DK. Head and neck injury: Predictors of ischemic stroke. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.

Ver todos los episodios